A binary dual-stain immunohistochemistry classifier to predict pathologic downstaging after neoadjuvant chemotherapy in muscle-invasive bladder cancer. This is an ASCO Meeting Abstract from the 2026 ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis. Survival is comparably poor for patients who develop metastases directly after non-muscle invasive ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus ...

Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical ...

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...

A validated risk score based on 12 aging-related genes (ARGs) in bladder cancer showed "considerable potential" as an independent predictor of clinical prognosis in patients with newly diagnosed ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

Subsequent treatments and outcomes in bacillus Calmette-Guerin–unresponsive patients with high-risk non-muscle invasive bladder cancer with carcinoma in situ: A real-world data analysis. This is an ...